Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed that Andrew Aristidou, Executive Director & CFO has ceased to be a Director & CFO of the Company from close of the business hours on 31st December, 2017.
The above information is a part of company’s filings submitted to BSE.